Satohiro Masuda
9PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Sep 27, 2024
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.Satohiro Masuda, Florian Lemaitre, Markus J Barten
|Jun 24, 2020
CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients.Yuki Yamamoto, Hiroshi Nakase, Minoru Matsuura
|Apr 29, 2020
Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients.Mengyu Zhang, Soichiro Tajima, Tomohiro Shigematsu
|Sep 25, 2019
Urinary Human Epididymis Secretory Protein 4 as a Useful Biomarker for Subclinical Acute Rejection Three Months after Kidney Transplantation.Soichiro Tajima, Rao Fu, Tomohiro Shigematsu
|Jul 03, 2019
Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities.Wei Zhang, Nobuaki Egashira, Satohiro Masuda
|Jun 28, 2019
Neutrophil Gelatinase-Associated Lipocalin Is Not Associated with Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients Who Received Mycophenolate Mofetil with Delayed Introduction of Tacrolimus.Mio Fukuda, Kimitaka Suetsugu, Soichiro Tajima
Pageof 2
